Endocrinology

• Guide and Post Graduate teacher for DNB Endocrinology students since 20 years at P.D. Hinduja National Hospital & Medical Research Centre.
• Member – Maharashtra University of Health Sciences (MUHS) Board of Studies Committee for Medicine and Allied- Superspeciality courses.
• Teacher for Diploma Dibetology candidates under College of Physicians & Surgeons at Hinduja Healthcare Surgical, Khar, Mumbai.
• Teacher for Diabetes Diploma Students at Bombay University for 7 years.
• 8 years of experience as a Postgraduate Teacher for General Medicine at Seth G.S. Medical College & KEM Hospital, Mumbai.
• Co-guide to student doing Post Graduate Diploma Course in Clinical Nutrition and Dietetics of SVT College of Home Science, SNDT Women's University, Juhu.
• Teacher for Fellowship in Diabetology at P.D. Hinduja National Hospital & Medical Research Centre, Mahim, Mumbai.
• Resource Person for ongoing Nursing Education programmes at P.D. Hinduja National Hospital & Medical Research Centre.

• Association of Physician of India
• Endocrine Society of India
• Maha Endocrine Society
• Endocrine Society (USA)
• Indian Academy of Paediatrics
• Menopause Society of India
• Indian Society for Paediatric and Adolescent Endocrinology
• Indian Society of Bone Metabolism and Research

Publications-

• Numerous publications in indexed and peer-reviewed national and international journals.
• Chapters in textbooks, clinical books of Diabetes, Reproductive Endocrinology and General Medicine.

Research-

As Principal Investigator:

• A Multicenter, Double-Blind Study to Determine the Efficacy and Safety of SYR-322 plus Pioglitazone HCl, (Actos ®), SYR-322 Alone or Pioglitazone HCl Alone in Subjects with Type 2 Diabetes.
• "Open non-comparative, multi-centre study to determine the efficacy and safety of Rimonabant in overweight or obese subjects".
• A Randomized, Double-Blind Study with an Open-Label Extension Comparing the Effect of Once-Weekly Dulaglutide with Placebo in Pediatric Patients with Type 2 Diabetes Mellitus.- 2017.
• Ongoing- Multicentric T1D1 study at P. D. Hinduja National Hospital and M.R.C., Mumbai.

As Co-Investigator:

• A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination with Metformin IR or Metformin XR in Pediatric Patients with Type 2 Diabetes who have Inadequate Glycemic Control.- 2006
• Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents with Type 2 Diabetes.- 2009
• Randomized, placebo controlled clinical trial to assess the safety and efficacy of Odanacatib (Mk-0822) to reduce the fracture in osteoporotic postmenopausal women treated with Vitamin D and Calcium.- 2009
• Registry of People with Diabetes in India with Young Age at Onset.- 2012
• Effect of liraglutide or glimepiride added to metformin on blood glucose control in subjects with type 2 diabetes.- 2013
• Control on Metformin Alone.A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients with Type 2 Diabetes Mellitus: the Element 5 Study.- 2019
• A 24 week Prospective Non-Interventional Post-Marketing Surveillance Study on Adverse Events and Serious Adverse Events in Patients with Type 2 Diabetes Mellitus in India being started on Dulaglutide (Trulicity™)- 2018
• “A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (≥10 to 18 years) with Type 2 Diabetes Mellitus.- 2018
• Semaglutide outcome trial in cardivascular events.- 2019
• A registry for secondary fracture prevention service, implemented by healthcare systems for the treatment of Osteoporotic patients.- 2019
• Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Prandial Technosphere® Insulin Inhalation Powder Versus Placebo Inhalation Powder in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Oral Antidiabetic Drugs Over a 24-week Treatment Period. – 2020